Remote Electromagnetic Control of Neural Activity for Treatment of Parkinson's Disease

神经活动的远程电磁控制治疗帕金森病

基本信息

  • 批准号:
    9890014
  • 负责人:
  • 金额:
    $ 66万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-07-01 至 2022-03-31
  • 项目状态:
    已结题

项目摘要

Project Summary In this collaborative and interdisciplinary application, we propose to develop further a novel non-invasive method for cell regulation (NICR) that is suitable for preclinical proof of concept studies. This technology potentially could be used to treat neurologic diseases and provide a less invasive alternative to deep brain stimulation (DBS) or optogenetics. We thus propose to refine the technology and develop a prototype device to test the use of NICR for the treatment of symptoms of Parkinson's Disease (PD) in mice. Cell activity is controlled by two components; the iron binding ferritin protein that spontaneously forms 5 nm iron nanoparticles and TRPV1, a temperature and mechano-sensitive channel. By tethering ferritin to TRPV1, one can gate the channel with radiofrequency (RF) (which heat or induce mechanical motion of ferritin) or a magnet (which induces motion). The method has been shown to be capable of controlling neural activity in vitro and in vivo, the latter by increasing neural firing. In addition, we have introduced a mutation into TRPV1 that converts it into a chloride channel, and the use of the mutant channel makes it possible to inhibit neural activity using electromagnetic waves (e.g., RF). Because the system is genetically encoded, one can regulate the activity of cells into which the two protein components of the system have been delivered by recombinant Adeno- Associated Virus (AAV) strains. AAV has been used in numerous human studies including patients with PD. Thus NICR could provide a less invasive alternative to implanted electrodes (DBS) or implanted light devices (optogenetics) for the modulation of neural activity (deep brain stimulation) and also be used to simultaneously control several different nodes in a neural circuit. In this application, we propose a set of preclinical proof-of-concept studies for the treatment of PD including: 1) refinement of the technology to improve its efficiency and to create suitable AAV strains to ameliorate the symptoms of PD. We also propose to increase the sensitivity of the system by using channels that can be gated with lower field strength and by identifying variants of ferritin with enhanced sensitivity to an electromagnetic field; 2) development of a prototype device that would create local electromagnetic fields of suitable strength with the aim of enabling the use of the method in routine laboratory settings and ultimately as a portable/wearable device; 3) testing the ability of the improved method and suitable instrumentation to alleviate the symptoms of PD in mice; and 4) creating knockin mice with cre dependent expression of the constructs to assess the safety of long term TRPV1 and ferritin expression. The validation of this technology could also lead to its use for the treatment of other diseases at sites within and outside the nervous system to either increase or decrease cell activity or regulate protein production. Finally, the further development of NICR could impact basic research by allowing the non-invasive activation or inhibition of cells by simply mating genetically modified mice and exposing them to RF or magnetic fields.
项目总结

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The sympathetic nervous system in the 21st century: Neuroimmune interactions in metabolic homeostasis and obesity.
  • DOI:
    10.1016/j.neuron.2022.10.017
  • 发表时间:
    2022-11-02
  • 期刊:
  • 影响因子:
    16.2
  • 作者:
    Martinez-Sanchez, Noelia;Sweeney, Owen;Sidarta-Oliveira, Davi;Caron, Alexandre;Stanley, Sarah A.;Domingos, Ana, I
  • 通讯作者:
    Domingos, Ana, I
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jonathan S. Dordick其他文献

Role, binding properties, and potential therapeutical use of glycosaminoglycans and mimetics in SARS-CoV-2 infection. In memory of Dr. Robert Linhardt (1953–2025)
糖胺聚糖及其模拟物在 SARS-CoV-2 感染中的作用、结合特性和潜在治疗用途。纪念罗伯特·林哈特博士(1953-2025 年)
  • DOI:
    10.1016/j.carbpol.2025.123703
  • 发表时间:
    2025-08-15
  • 期刊:
  • 影响因子:
    12.500
  • 作者:
    Vitor H. Pomin;Fuming Zhang;Jonathan S. Dordick
  • 通讯作者:
    Jonathan S. Dordick
Patents and literature biocatalysis in nonaqueous media
Facile pretreatment of lignocellulosic biomass at high loadings in room temperature ionic liquids
在室温离子液体中高负载量轻松预处理木质纤维素生物质
  • DOI:
    10.1002/bit.23266
  • 发表时间:
    2011-12
  • 期刊:
  • 影响因子:
    3.8
  • 作者:
    Hong Wu;Mauricio Mora-Pale;Jian-Jun Miao;Thomas V. Doherty;Robert J. Linhardt;Jonathan S. Dordick
  • 通讯作者:
    Jonathan S. Dordick
Enzyme-based formulations for decontamination: current state and perspectives
  • DOI:
    10.1007/s00253-013-4797-x
  • 发表时间:
    2013-03-10
  • 期刊:
  • 影响因子:
    4.300
  • 作者:
    Navdeep Grover;Cerasela Zoica Dinu;Ravi S. Kane;Jonathan S. Dordick
  • 通讯作者:
    Jonathan S. Dordick
Endolysin-based autolytic E. coli system for facile recovery of recombinant proteins
基于内溶素的自溶大肠杆菌系统,可轻松回收重组蛋白
  • DOI:
    10.1021/acs.jafc.1c00059
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    6.1
  • 作者:
    Jian Zha;Zhiqiang Liu;Runcong Sun;Guoli Gong;Jonathan S. Dordick;Xia Wu
  • 通讯作者:
    Xia Wu

Jonathan S. Dordick的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jonathan S. Dordick', 18)}}的其他基金

High-Throughput Platform for Identifying Stem Cell Toxicity
用于识别干细胞毒性的高通量平台
  • 批准号:
    8217894
  • 财政年份:
    2011
  • 资助金额:
    $ 66万
  • 项目类别:
High-Throughput Platform for Identifying Stem Cell Toxicity
用于识别干细胞毒性的高通量平台
  • 批准号:
    8404019
  • 财政年份:
    2011
  • 资助金额:
    $ 66万
  • 项目类别:
High-Throughput Platform for Identifying Stem Cell Toxicity
用于识别干细胞毒性的高通量平台
  • 批准号:
    8573021
  • 财政年份:
    2011
  • 资助金额:
    $ 66万
  • 项目类别:
Development of a Bioengineered Heparin from a Non-Animal Source
开发非动物来源的生物工程肝素
  • 批准号:
    8294884
  • 财政年份:
    2009
  • 资助金额:
    $ 66万
  • 项目类别:
An Artificial Golgi: Controlled GAG Synthesis and Screening
人工高尔基体:受控 GAG 合成和筛选
  • 批准号:
    7945295
  • 财政年份:
    2009
  • 资助金额:
    $ 66万
  • 项目类别:
Development of a Bioengineered Heparin from a Non-Animal Source
开发非动物来源的生物工程肝素
  • 批准号:
    8016845
  • 财政年份:
    2009
  • 资助金额:
    $ 66万
  • 项目类别:
Development of a Bioengineered Heparin from a Non-Animal Source
开发非动物来源的生物工程肝素
  • 批准号:
    7699173
  • 财政年份:
    2009
  • 资助金额:
    $ 66万
  • 项目类别:
Development of a Bioengineered Heparin from a Non-Animal Source
开发非动物来源的生物工程肝素
  • 批准号:
    7904164
  • 财政年份:
    2009
  • 资助金额:
    $ 66万
  • 项目类别:
Development of a Bioengineered Heparin from a Non-Animal Source
开发非动物来源的生物工程肝素
  • 批准号:
    8463596
  • 财政年份:
    2009
  • 资助金额:
    $ 66万
  • 项目类别:
Development of a Bioengineered Heparin from a Non-Animal Source
开发非动物来源的生物工程肝素
  • 批准号:
    8080427
  • 财政年份:
    2009
  • 资助金额:
    $ 66万
  • 项目类别:

相似海外基金

Exploiting and enhancing IgE-binding epitopes of the 2S albumins of peanuts and tree nuts
利用和增强花生和坚果 2S 白蛋白的 IgE 结合表位
  • 批准号:
    10685312
  • 财政年份:
    2021
  • 资助金额:
    $ 66万
  • 项目类别:
Exploiting and enhancing IgE-binding epitopes of the 2S albumins of peanuts and tree nuts
利用和增强花生和坚果 2S 白蛋白的 IgE 结合表位
  • 批准号:
    10490872
  • 财政年份:
    2021
  • 资助金额:
    $ 66万
  • 项目类别:
Exploiting and enhancing IgE-binding epitopes of the 2S albumins of peanuts and tree nuts
利用和增强花生和坚果 2S 白蛋白的 IgE 结合表位
  • 批准号:
    10345963
  • 财政年份:
    2021
  • 资助金额:
    $ 66万
  • 项目类别:
Development of Highly Functionalized Serum Albumins as Boron Delivery Carries to Tumor for Neutron Capture Therapy
开发高功能化血清白蛋白作为硼输送至肿瘤以进行中子捕获治疗
  • 批准号:
    17H02202
  • 财政年份:
    2017
  • 资助金额:
    $ 66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Studies on Asymmetric Nitroaldol Reaction using mutant albumins
突变体白蛋白不对称硝醛醇反应的研究
  • 批准号:
    16K05706
  • 财政年份:
    2016
  • 资助金额:
    $ 66万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
SPIN LABELING STUDIES OF NORMAL RECOMBINANT & MUTANT HUMAN SERUM ALBUMINS
正常重组的旋转标记研究
  • 批准号:
    6118869
  • 财政年份:
    1999
  • 资助金额:
    $ 66万
  • 项目类别:
COPPER BINDING OF COMMERCIAL, NORMAL RECOMBINANT, & MUTANT HUMAN SERUM ALBUMINS
商业、正常重组的铜结合,
  • 批准号:
    6118864
  • 财政年份:
    1999
  • 资助金额:
    $ 66万
  • 项目类别:
Structure and Metabolism of the Serum Albumins Characteristic of Bisalbuminemia in Fowl
家禽双清蛋白血症血清白蛋白的结构与代谢特征
  • 批准号:
    67B6472
  • 财政年份:
    1967
  • 资助金额:
    $ 66万
  • 项目类别:
Structure and Metabolism of the Serum Albumins Characteristic of Bisalbuminemia
双清蛋白血症血清白蛋白的结构和代谢特征
  • 批准号:
    65B3344
  • 财政年份:
    1965
  • 资助金额:
    $ 66万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了